Patents by Inventor Byron H. Arison

Byron H. Arison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbial transformation of simvastatin
    Patent number: 4997849
    Abstract: Compounds of formula (I) and (II): ##STR1## are HMG-CoA reductase inhibitors.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: March 5, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Brian R. Petuch, Byron H. Arison
  • FK-520 microbial transformation product
    Patent number: 4987139
    Abstract: Described is a new immunosuppressant, L-687,795, a C-13, C-15, C-31 trisdemethylated, ring rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, Actinoplanacete sp. (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: May 5, 1989
    Date of Patent: January 22, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, Linda S. Wicker, Byron H. Arison
  • Immunosuppressant compound
    Patent number: 4981792
    Abstract: Described is a process for producing a new immunosuppressant, "demethomycin" (L-682,993) a C-31 demethylated analog of L-679,934 under novel fermentation conditions utilizing the microorganism, Actinoplanacete sp., (Merck Culture Collection MA 6559) ATCC No. 53771. The macrolide immunosuppressant is useful in prevent human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: January 1, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Edward S. Inamine, Byron H. Arison, Shieh-Shung T. Chen, Linda S. Wicker
  • Microbial transformation product of L-683,590
    Patent number: 4975372
    Abstract: Described is a new immunosuppressant, L-685,487, a monodemethylated rearranged derivative of L-683,590, produced under fermentation conditions utilizing the microorganism, unidentified Actinomycete (Merck Cultrue Collection MA 6474) ATCC No. 53828. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: January 13, 1989
    Date of Patent: December 4, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
  • Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
    Patent number: 4965200
    Abstract: A biotransformation for the formation of a 3-keto-5-hydroxy simvastation analog (I) or a 8-acyloxy derivative thereof is disclosed.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: October 23, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung J. Chen, Byron H. Arison
  • HMG-CoA reductase inhibitors
    Patent number: 4738982
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II): ##STR1## and pharmaceutically acceptable salts thereof the compounds of the formula (II) in which R is hydrogen are disclosed.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: April 19, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Michael D. Greenspan, Joel B. Yudkovitz
  • Novel derivatives of C-076 compounds
    Patent number: 4285963
    Abstract: There are disclosed certain new derivatives of C-076 compounds which have been isolated from the fermentation broth that produced the original C-076 compounds. The compounds retain the C-076 16-membered cyclic backbone, however, the groups attached thereto are considerably modified from the original C-076 compounds. The new compounds have been found to retain the biological activity of the parent C-076 compounds. The compounds are thus potent antiparasitic agents and compositions and methods for such uses are also disclosed.
    Type: Grant
    Filed: August 7, 1980
    Date of Patent: August 25, 1981
    Assignee: Merck & Co., Inc.
    Inventors: Byron H. Arison, Robert T. Goegelman, Vincent P. Gullo